NCT06336174 Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
| NCT ID | NCT06336174 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anhui Medical University |
| Condition | Intracranial Atherosclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-11-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-11-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to explore the mechanism of cognitive impairment in patients with symptomatic intracranial atherosclerotic stenosis (ICAS), and further plans to explore the impact of different treatment options on cognitive function in symptomatic ICAS patients.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 80 years * Severe stenosis (≥70%-99%) of atherosclerotic internal carotid artery (C6 segment, C7 segment) or middle cerebral artery (M1 segment) confirmed by digital subtraction angiography (DSA) or at least two of the following non-invasive examinations: magnetic resonance angiography (MRA), computed tomography angiography (CTA), or transcranial Doppler (TCD) * Transient ischemic attack (TIA) or minor stroke (National Institute of Health Stroke Scale \[NIHSS\] score ≤ 4 points) * Right-handed and able to cooperate in neuropsychological tests * At least 14 days post-onset of cerebral infarction or TIA * Signed informed consent Exclusion Criteria: * Other diseases that affect cognitive function, such as cerebral hemorrhage, •Parkinson's disease, neurosyphilis, dementia, tumors, etc. * Right upper limb hemiplegia, aphasia, visual field defects, or visual impairments * More than 50% stenosis of the extracranial internal carotid artery, the vertebral artery, or the basilar artery * Vasculitis, moyamoya disease, and cardiogenic stroke * Previous history of head and neck stent implantation, carotid endarterectomy, aneurysm embolization, or other intracranial surgeries
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06336174 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Intracranial Atherosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06336174 currently recruiting?
Yes, NCT06336174 is actively recruiting participants. Contact the research team at wangkai1964@126.com for enrollment information.
Where is the NCT06336174 trial being conducted?
This trial is being conducted at Hefei, China.
Who is sponsoring the NCT06336174 clinical trial?
NCT06336174 is sponsored by Anhui Medical University. The trial plans to enroll 100 participants.